Swiss Healthtech Stock News

Goldman Sachs upgrade puts Flughafen Zürich in focus Goldman Sachs has upgraded Flughafen Zürich (SWX:FHZN) to Buy, highlighting what it describes as a supportive investment profile as geopolitical reopening broadens and potentially influences traffic across key European airports. See our latest analysis for Flughafen Zürich. The upgrade comes after a sharp rebound in market sentiment, with the share price up 13.48% over the past month and 7.24% over the past week. The 1 year total...

Lonza Group (SWX:LONN) has signed fresh licensing agreements with Antharis Therapeutics and Stipple Bio, giving both biotechnology partners access to its antibody drug conjugate technology for oncology programs and positioning Lonza as a key supplier. See our latest analysis for Lonza Group. These oncology licensing deals arrive as the stock posts a 5.45% 1 month share price return and a 0.96% 1 day gain, while the 1 year total shareholder return is down 11.78%. This points to improving short...

Cosmo N.V. has recently announced that its partner InfectoPharm has launched Winlevi, a first-in-class topical acne cream using clascoterone, in Austria and Germany following European Commission approval. This rollout deepens Cosmo’s dermatology footprint in Europe and highlights the commercial potential of its role as exclusive global manufacturer of Winlevi. We’ll now examine how Winlevi’s European rollout, including the Austria and Germany launches, could influence Cosmo’s broader...

Why the Los Angeles expansion matters for Vontobel Holding shareholders Vontobel Holding (SWX:VONN) has opened a new office in Los Angeles, extending its Swiss Financial Advisers presence closer to US-based clients seeking international diversification across custody and investing. This expansion gives the Swiss group a foothold in one of the largest US wealth hubs while keeping its focus on tailored services, fiduciary standards and alignment with both Swiss and US regulations. See our...

Voter approval clears path for Lebensraum Metalli Zug Estates Holding (SWX:ZUGN) is moving ahead with its Lebensraum Metalli project after Zug voters approved the Metalli development plan, a decision that gives investors clearer sightlines on future project driven opportunities. See our latest analysis for Zug Estates Holding. Despite the positive Metalli vote, the stock’s recent momentum has cooled, with the 30 day share price return down 6.33% and the 90 day move down 11.91%. However, the 3...

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Event-driven focus on Zurich Insurance Group (SWX:ZURN) Zurich Insurance Group (SWX:ZURN) has come into focus after being highlighted as a top European dividend stock, with a 4.40% yield, at a time when the STOXX Europe 600 Index has recently declined. See our latest analysis for Zurich Insurance Group. The current share price of CHF563.8 sits alongside a 4.8% 90 day share price return and a 6.0% one year total shareholder return, while the five year total shareholder return of 95.8% reflects...

ABB’s AI data center push with NVIDIA ABB (SWX:ABBN) is back in focus after announcing the next phase of its collaboration with NVIDIA, integrating its SimReady digital twins into NVIDIA Omniverse DSX for AI data center power design. This move links ABB’s power systems directly to AI focused design workflows, providing data center developers with tools to model, test, and refine power distribution and energy efficiency at scale before any physical construction begins. See our latest analysis...

Switzerland’s upcoming vote on a population cap is putting immigration, growth, and access to talent under the spotlight, and that flows directly into many portfolios. While large multinationals grab the headlines, a quieter group of Swiss-focused stocks may see different ripple effects, because a bigger share of their revenue and workforce is tied to the domestic economy. This article highlights 3 stocks from the Swiss Domestic Focused Companies screener that appear relatively better...

Swisscom downgrade puts revenue stability and Italy execution in focus Morgan Stanley’s downgrade of Swisscom (SWX:SCMN) to Underweight puts the spotlight on the company’s ability to keep revenues steady, squeeze out further efficiencies and manage a rigid capital spending plan. The report also highlights execution risks in Swisscom’s Italian business, which the broker still views as an area with cash flow potential. This makes the stock’s risk profile a key talking point for investors. See...

PremiStar, a portfolio company of Partners Group Holding, is expanding its US footprint with the acquisition of Mechanical Service & Systems (MSS) in Utah. The deal adds a new regional platform to PremiStar’s mechanical contracting and services network across the United States. This transaction highlights Partners Group’s ongoing focus on consolidating regional operators in infrastructure related services. For investors tracking Partners Group Holding (SWX:PGHN), the acquisition of MSS into...

UBS Group triggered article: recent performance snapshot UBS Group (SWX:UBSG) has drawn investor attention after recent trading, with the stock closing at CHF 37.53 and showing mixed short term moves, including a small decline over the past day. Over the past week UBS Group has been broadly flat. The stock is up over the past month and past 3 months, set against a market value of about CHF 114.1b. See our latest analysis for UBS Group. Looking beyond the latest CHF 37.53 share price, UBS...

ams-OSRAM (SWX:AMS) is back in focus after divesting non optical sensor businesses and sharpening its push into digital photonics, while consensus EPS estimates for the quarter have been revised sharply higher. See our latest analysis for ams-OSRAM. That sharper focus on digital photonics and the recent EPS estimate upgrade sit against a share price of CHF16.86, with a 90 day share price return of 105.86% and a 1 year total shareholder return of 88.38%, even though the 3 and 5 year total...

Nestlé (SWX:NESN) is rolling out a broad turnaround plan under CEO Philipp Navratil, centered on workforce restructuring and a sharper focus on core and high growth brands. The plan includes a global restructuring program affecting 16,000 jobs, alongside portfolio changes such as the divestment of its Chilean water joint venture. The company is also pursuing new acquisitions while negotiating measures in key regions to limit the impact of job reductions. Nestlé, one of the largest global...

Temenos share performance snapshot Temenos (SWX:TEMN) has drawn investor attention after a period of weaker recent share performance, with the stock down 1% over the past day, 2% over the past week, and 8% over the past month. See our latest analysis for Temenos. At a share price of CHF67.3, Temenos has seen pressure on short term momentum, with the 90 day share price return down 10.98%, while the 1 year total shareholder return of 7.09% contrasts with longer term 3 and 5 year total...

Cosmo (SWX:COPN) is back in focus after partner Glenmark Specialty S.A. began rolling out Winlevi cream across several European countries, following European Commission approval for treating acne in adults and adolescents. See our latest analysis for Cosmo. Despite the Winlevi rollout and Cosmo presenting at the Jefferies Global Healthcare Conference, the CHF70.5 share price is down 21.93% on a 90 day share price return and 33.11% on a year to date share price return. At the same time, the 1...

What recent trading tells you about Landis+Gyr Group (SWX:LAND) Landis+Gyr Group (SWX:LAND) has drawn attention after a mixed stretch in the stock, with a modest gain over the past month set against declines over the past 3 months and year. See our latest analysis for Landis+Gyr Group. At a share price of CHF48.95, Landis+Gyr Group has seen short term momentum cool, with the 7 day share price return down 6.94% and the 1 year total shareholder return down 9.15%. This points to fading...

As European markets navigate a period of uncertainty marked by economic contractions and fluctuating retail sales, investors are increasingly focused on identifying opportunities that offer attractive valuations. In this context, finding stocks trading below their estimated intrinsic values can be a prudent strategy for those looking to capitalize on potential market inefficiencies.

If you are wondering whether Sandoz Group stock still offers value at current levels, or if the recent run has already priced in the opportunity, this article breaks down what the market might be implying about the company. The stock last closed at CHF 64.60, with returns of 2.7% over the past week, a decline of 3.4% over the past month, 12.9% year to date, and 50.5% over the past year. This performance may catch the eye of investors tracking momentum and changing risk perceptions. Recent...

Why this new loan matters for Idorsia shareholders Idorsia (SWX:IDIA) has agreed a senior secured term loan facility of up to CHF 250 million with funds managed by Pharmakon Advisors, a move that directly reshapes the company’s near term debt profile. The first CHF 150 million tranche will refinance Idorsia’s existing New Money Facility, removing upcoming maturities linked to the CHF 105 million already drawn and extending breathing room beyond the May 2027 deadline. See our latest analysis...

The aluminum sector is suddenly in the spotlight as tariffs, supply disruptions in the Middle East, and shifting trade routes push prices to a four year high and reroute flows of metal across borders. For investors, this mix of pressure and opportunity can quickly separate the strongest producers from the rest. This article highlights 3 aluminum stocks from our screener that are directly exposed to these developments, from soaring US Midwest premiums to a surge in Canadian exports to Europe...

Roche Holding (SWX:ROP) and Nurix Therapeutics announced a global collaboration to co-develop and co-commercialise bexobrutideg, a novel BTK degrader. The partnership targets hematology, immunology, and neurology indications, aiming to address resistance seen with existing BTK inhibitors. The deal expands Roche's exposure to targeted protein degradation therapies and adds a new pillar to its R&D and commercial plans. Roche Holding, trading at around CHF322.7, is entering this alliance from...

Why Dottikon ES Holding’s Latest Earnings Matter for Investors Dottikon ES Holding (SWX:DESN) has drawn fresh attention after reporting full year results to March 31, 2026, with higher sales of CHF 428.44 million, alongside slightly lower net income and earnings per share. See our latest analysis for Dottikon ES Holding. The latest results arrived after a weaker share price patch, with the stock down 19% on a 30 day share price return and 17.98% on a year to date share price return. Even so,...

Compagnie Financière Tradition (SWX:CFT) is back on investors’ radar after a recent share move, which has coincided with fresh interest in how its earnings profile and valuation currently stack up. See our latest analysis for Compagnie Financière Tradition. Recent trading reflects that tension between growth and valuation, with the share price at CHF282.0 after a 7 day share price return of 5.2% but a 30 day share price return that is down 5.2%. At the same time, the 1 year total shareholder...